CN101869687B - Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase - Google Patents
Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase Download PDFInfo
- Publication number
- CN101869687B CN101869687B CN2010102011040A CN201010201104A CN101869687B CN 101869687 B CN101869687 B CN 101869687B CN 2010102011040 A CN2010102011040 A CN 2010102011040A CN 201010201104 A CN201010201104 A CN 201010201104A CN 101869687 B CN101869687 B CN 101869687B
- Authority
- CN
- China
- Prior art keywords
- liver
- parts
- fatty liver
- medicament
- zinc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention relates to a medicament for treating liver diseases and reducing blood lipid, in particular to a medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase, and solves the problem of treating the fatty liver and alcohol liver. The medicament is prepared from the following raw materials: Chinese caterpillar fungus, ginseng, hawthorn, kudzu-vine root, turmeric, liquoric root, cassia seed, Chinese magnoliavine fruit, oriental waterplantain rhizome, tea polyphenols, glycine, arginine, vitamin E, folic acid and zinc. The results of the animal experiments and human clinical experiments show that the medicament of the invention has excellent effects of treating and preventing fatty liver.
Description
Technical field
The present invention relates to a kind of treatment hepatopathy, the medicine of blood fat reducing is specially a kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering.
Background technology
Fatty liver is because the too much disease of liver fat accumulation that a variety of causes causes, fat content accounts for 2% to 4% of liver weight in wet base in normal person's the liver, fat content is gathered and is surpassed 5% o'clock visible fat drop of microscopically observation liver section in the liver, is referred to as fatty liver.Can be divided into alcoholic fatty liver and non-alcoholic fatty liver disease according to the cause of disease, the people of modern society is because multiple bad living and diet custom, as long-term excessive drinking, to take in higher fatty acid and high confectionery thing, obesity, diabetes etc. for a long time be to cause the principal element of alcoholic liver, fatty liver.Alcoholic liver, fatty liver very easily make progress and are serious diseases such as hepatitis, hepatic fibrosis and liver cirrhosis.
For many years, the treatment of fatty liver never has effective medicine clinically, general lipid lowerers and the Chinese medicine hepatoprotective of adopting of treatment.Owing to take lipid lowerers and can increase the weight of hepar damnification, cause that the transaminase raises and the weight fat liver, therefore more careful usefulness in clinical treatment.Chinese medicine protects the liver that mechanism is indeterminate, and action target spot is unclear, thereby causes curative effect not good enough.Therefore people have just produced fatty liver and can't treat the puzzlement that no medicine can be cured.
In the last few years, the medical experts that are engaged in the fatty liver clinical research abroad for many years are through a large amount of clinical trials and the research of scientific theory, several theories of fatty liver generation development have been proposed, for example: the unusual theory of lipid metabolism, the liver theory that is short of power, the peroxide injury theory, two-hit theory etc.Study abroad silver-colored little doctor Long who is engaged in modern molecular biology research for many years in U.S.A and think that fat (mainly being triglyceride) gathering in hepatocyte is the main cause that forms fatty liver.Thinking that in the past the simple fatty liver harm is little, is hardened early stage of (ethanol and non-alcoholic) fat hepatitis regulating liver-QI but medical research in recent years shows fatty liver.Fatty liver is often directly related with the metabolism disorder syndrome, and clinical marker is obesity, hypertonicity, insulin resistant, carbohydrate tolerance is impaired and hyperlipidemia etc.Fat and metabolism disorder syndrome cause the formation mechanism of the mechanism of fatty liver and alcoholic fatty liver similar.Patients with Fatty Liver continues to drink and can cause fat hepatitis and hepatic fibrosis and then develop into liver cirrhosis.Similar therewith, non-alcoholic fatty liver disease also can cause hepar damnification, hepatic fibrosis and liver cirrhosis.
The significant quantities of fat that accumulates in liver influences the hepatocyte metabolism and hepatitis takes place, and can cause liver cirrhosis, hepatocarcinoma.Because the liver fat turn-over capacity descends, the lipid metabolism malfunction, produce and stored a large amount of triglyceride and cholesterol in the liver, when blood enter that liver purifies and when detoxifying a large amount of triglyceride and cholesterol brought into blood, cause hyperlipidemia, the blood stickiness is increased, and initiation hypertension, form atherosclerosis, further develop and cause myocardial infarction, cerebral thrombosis and sudden cardiovascular and cerebrovascular diseases to cause death and permanent disability.The key of fatty liver treatment will shift out liver with accumulating in liver excess fat such as triglyceride, cholesterol etc. exactly.
Summary of the invention
The present invention provides a kind of treatment fatty liver, alcoholic liver, the medicine of blood fat reducing, transaminase lowering for the problem that solves treatment fatty liver, alcoholic liver.
The present invention is realized by following technical scheme, a kind of treatment fatty liver, alcoholic liver, and the medicine of blood fat reducing, transaminase lowering is to be made by the raw material of following weight ratio example,
Cordyceps 5-10 part, Radix Ginseng 30-35 part, Fructus Crataegi 50-80 part, Radix Puerariae 90-95 part, Rhizoma Curcumae Longae 45-50 part, Radix Glycyrrhizae 30-50 part, Semen Cassiae 28-30 part, Fructus Schisandrae Chinensis 30-50 part, Rhizoma Alismatis 20-30 part, tea polyphenols 12-15 part, glycine 20-30 part, arginine 10-20 part, vitamin E 0.5-0.8 part, folic acid 0.6-0.9 part, zinc 0.01-0.02 part.
Cordyceps is a kind of rare Chinese medicine of China, classifies China's three big tonics as with Radix Ginseng, Cornu Cervi Pantotrichum.As far back as a Seventh Five-Year Plan record of " Cordyceps Gan Pingbao lung, kidney tonifying are mended marrow, hemostasis and phlegm, phthisical cough, it is all good to control diaphragm disease " was just arranged in 7 years in " Bencao Congxin ".The traditional Chinese medical science thinks that Cordyceps goes into lung kidney two warps, can tonifying the lung the moon, again can kidney-replenishing, and cure mainly and suffer from a deficiency of the kidney, impotence and seminal emission, soreness of waist and knee joint, weak after being ill, the chronic cough weakness, phthisical cough expectorant blood, spontaneous sweatings etc. are unique a kind of balances simultaneously, regulate the Chinese medicine of negative and positive.The main component of Fructus Crataegi is a Flavonoid substances, in addition, contains organic acid such as chlorogenic acid, caffeic acid and tannin in the Fructus Crataegi, the acid anhydride of tanning, epicatechol, choline, acetylcholine, Sitosterolum, carotene and lot of V C etc.Radix Ginseng can increase the enzymatic activity of each material of liver metabolism, the detoxification ability of liver is strengthened, thereby enhancing body is to the tolerance of various chemical substances.Fructus Schisandrae Chinensis can quicken the metabolic rate of acetaminophen and lower the GSH consume, helps the liver protecting.Human test result shows that Fructus Schisandrae Chinensis is especially effective for suffering from the due to illness malicious chronic hepatitis person's (comprising A type, Type B, C type, D type and E type) who is caused.Fructus Schisandrae Chinensis has antiinflammation, to prevent hepar damnification, activates anabolic process promoting impaired hepatocellular reparation, and can strengthen the activity of DNA (DNA) synthetic and ODC Ornithine decarboxylase, the regeneration liver cell.Radix Puerariae energy hypoglycemic, Radix Puerariae have the effect of tangible blood sugar lowering, and the contained flavone compound of Radix Puerariae has effect for reducing blood fat, can reduce serum cholesterol, and triglyceride reducing is used for the treatment of hyperglycemia, and the hyperlipidemia disease has significant curative effect.Rhizoma Curcumae Longae has that blood fat reducing is antiphlogistic to influence the cardiovascular system effect; Radix Glycyrrhizae has enhancing and suppresses body's immunity; antibiotic, antiviral, antiinflammatory, glycyrrhiza preparation and glycyrrhizin have significant protection to animal kinds of experiments liver damage, and blood fat reducing improves lipid system and liver function.Semen Cassiae also contains steroidal compounds, chrysophanol, emodin etc. except that containing saccharide, protein, fat, in addition the trace elements iron of needed by human, zinc, manganese, copper, nickel, cobalt, molybdenum etc.Contained emodin, chrysophanic acid human body is had relieving asthma, function of gallbladder promoting, protect the liver, the blood pressure lowering effect, and necessarily antibiotic, antiinflammation are arranged.Alisol A acetas, alisol B acetas and alisol C acetas can be protected the mouse liver because of carbon tetrachloride poisoning.
Said medicine is pulverized and is 50-80 order fine powder, mixes, and can make capsule, pill or tablets and other formulations and use.The present invention can effectively remove and transport the fat of hepatocyte inner accumulated with various material combination together, transaminase lowering, and the further pathological changes of prevention liver is repaired impaired hepatocyte, increases the ability of the synthetic apolipoprotein of hepatocyte.General severe fatty liver is taken medicine of the present invention and can be become moderate about 3 months, can remove fully, and revert to normal liver in moderate fatty liver 3-4 month.Thoroughly remove fatty liver, discharge toxin by said medicine, liver is new as becoming, neat and tidy, strong healthy health.Liver function recovers comprehensively, lipid metabolism is normal fully.Make liver quicken fat metabolism, burning fat and drain fat-removal to be gone out external, avoided fat in liver, heart and blood vessel, to deposit, reduced triglyceride and cholesterol by metabolism.Because medicine of the present invention adopts and the diverse mechanism of action of other lipid lowerers, thus this medicine impairing the liver not when regulating lipid metabolism and cholesterol reducing, but also effectively the liver protecting, remove fatty liver and transaminase lowering.By taking medicine blood fat reducing of the present invention, can avoid the generation of metabolism syndrome, reduce the harm of cardiovascular and cerebrovascular disease, remove the high risk factors of lethal such as causing apoplexy, myocardial infarction, coronary heart disease.
Show that by zoopery and clinical test results the present invention is respond well to treatment and prevention fatty liver.(1), zoopery
1, with the medicine of the listed raw material consumptions configuration of the embodiment of the invention 2 to rat feeding ethanol after to reducing the effect of blood alcohol concentration, see accompanying drawing 1
2, the medicine with the embodiment of the invention 2 listed raw material consumption configurations can significantly suppress TNF-α rising in the inductive blood of endotoxin LPS, two groups of rat LPS are induced the influence that produces TNF-α, see accompanying drawing 2, explanation can obviously reduce tumor necrosis factor level (TNF-α) in the blood that LPS induces generation.
3, with the medicine of the listed raw material consumptions configuration of the embodiment of the invention 2 rat stomach is raised the influence of glutamic oxaloacetic transaminase, GOT AST level in the ethanol bleeding from anus, see Fig. 3.
Zoopery shows that the present invention has obvious protective effect to the rat liver cell, gives the obviously recovery of acceleration of alcohol hepatocyte injury of medicine of the present invention, and quickens the serum transaminase level and recover; The present invention can obviously reduce rat serum, urine, excrement, expired gas and gastric content alcohol concentration, can be by activating or promoting that first-pass metabolism mechanism minimizing ethanol absorbs in gastrointestinal or the liver, promote alcohol metabolism, can obviously reduce LPS and induce the level that produces TNF-α.
No. 309 Hospital of People Liberation Anny's MEC in March, 2007～2008 year February to 120 (male 92 examples, woman's 28 examples) fatty liver and simple hyperlipemic patients (fatty liver 105 examples, hyperlipidemia 15 examples), take with before the medicine of the embodiment of the invention 1 listed raw material consumption configuration and after three months, twice blood fat, liver function, kidney merit and B ultrasonic iconography change before and after the monitoring.
Efficacy result shows: 105 routine Patients with Fatty Liver are cured 83 examples, produce effects 17 examples, invalid 5 examples, total effective rate 95.2%.Contrast before and after the biochemical indicator: serum triglycerides (TG) lowering of concentration 27%, low density lipoprotein, LDL (LDL) has reduced by 20%, glutamate pyruvate transaminase (ALT) has reduced by 48%, glutamyl transpeptidase (GGT) has reduced by 36%, blood urea nitrogen (BUN) has reduced by 39%, and fasting glucose, T-CHOL, high density lipoprotein, creatinine, uric acid change the difference not statistically significant.
Model case
1, Mr. Zhao, people from Xinzhou, Shanxi, 55 years old age, suffer from the moderate fatty liver, take the embodiment of the invention 1 described medicine after three courses of treatment liver recover normal, remove fully through the ultrasound diagnosis fatty liver.
2, Mrs Wang, people from Taiyuan City, 40 years old age, suffer from the moderate fatty liver, take the embodiment of the invention 2 described medicines after three courses of treatment liver recover normal, remove fully through the ultrasound diagnosis fatty liver.
3, Mr. Guo, people from Beijing, at 64 years old age, the professional manager suffers from severe fatty liver, diabetes, through taking 3 described Drug therapys of the embodiment of the invention after three courses of treatment liver normal, remove fully through the ultrasound diagnosis fatty liver, glycemic control is stable.
4, Mr. Zhu, 49 years old age, occupation, civil servant; Suffers from the moderate fatty liver; Often become a full member through liver after taking this Drug therapy, remove fully through the ultrasound diagnosis fatty liver.
Description of drawings
Fig. 1 is the influence of the present invention to rat feeding ethanol
Fig. 2 is for inducing the influence that produces TNF-α to two groups of rat LPS
Fig. 3 raises the influence of glutamic oxaloacetic transaminase, GOT AST level in the ethanol bleeding from anus to rat stomach for the present invention
The specific embodiment
Zinc can be selected inorganic zinc, and as zinc sulfate, zinc oxide, zinc carbonate, perhaps organic zinc is as zinc gluconate, zinc methionine etc.
Getting above-mentioned each raw material adds forming agent again and can make tablet, dosage forms such as pill, each dosage form is produced and is common process, preparing tablet as dry granulation sieves each raw material pulverizing exactly and granulates then after back and the binding agent mixing that tabletting gets final product, perhaps adopt wet granulation, with disintegrating agent, wetting agent and each raw material mixing after drying, granulate, tabletting gets final product.
Zinc can be selected zinc sulfate, zinc oxide, zinc carbonate, and perhaps organic zinc is as zinc gluconate, zinc methionine etc.Take by weighing said medicine and pulverize, be mixed and made into capsule and get final product to 50-80 order fine powder.
10 parts of Cordyceps, 30 parts of Radix Ginsengs, 80 parts of Fructus Crataegis, 90 parts of Radix Puerariaes, 50 parts in Rhizoma Curcumae Longae, 30 parts in Radix Glycyrrhizae, 30 parts of Semen Cassiaes, 30 parts of Fructus Schisandrae Chinensis, 30 parts of Rhizoma Alismatis, 12 parts of tea polyphenols, 30 parts of glycine, 10 parts of arginine, 0.8 part of vitamin E, 0.6 part in folic acid, 0.02 part on zinc.
Zinc can be selected zinc sulfate, zinc oxide, zinc carbonate, and perhaps organic zinc is as zinc gluconate, zinc methionine etc.Take by weighing the said medicine pulverizing and be 50-80 order fine powder, add and make pill after some binding materials mix.
Claims (2)
1. treat fatty liver, alcoholic liver for one kind, the medicine of blood fat reducing, transaminase lowering is characterized in that being made by the raw material of following weight ratio example,
Cordyceps 5-10 part, Radix Ginseng 30-35 part, Fructus Crataegi 50-80 part, Radix Puerariae 90-95 part, Rhizoma Curcumae Longae 45-50 part, Radix Glycyrrhizae 30-50 part, Semen Cassiae 28-30 part, Fructus Schisandrae Chinensis 30-50 part, Rhizoma Alismatis 20-30 part, tea polyphenols 12-15 part, glycine 20-30 part, arginine 10-20 part, vitamin E 0.5-0.8 part, folic acid 0.6-0.9 part, zinc 0.01-0.02 part.
2. treatment fatty liver according to claim 1, alcoholic liver, the medicine of blood fat reducing, transaminase lowering is characterized in that being made by the raw material of following weight ratio example,
7 parts of Cordyceps, 32 parts of Radix Ginsengs, 65 parts of Fructus Crataegis, 93 parts of Radix Puerariaes, 48 parts in Rhizoma Curcumae Longae, 40 parts in Radix Glycyrrhizae, 29 parts of Semen Cassiaes, 40 parts of Fructus Schisandrae Chinensis, 25 parts of Rhizoma Alismatis, 14 parts of tea polyphenols, 25 parts of glycine, 15 parts of arginine, 0.6 part of vitamin E, 0.8 part in folic acid, 0.015 part on zinc.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102011040A CN101869687B (en) | 2010-06-10 | 2010-06-10 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102011040A CN101869687B (en) | 2010-06-10 | 2010-06-10 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101869687A CN101869687A (en) | 2010-10-27 |
| CN101869687B true CN101869687B (en) | 2011-11-16 |
Family
ID=42994893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102011040A Active CN101869687B (en) | 2010-06-10 | 2010-06-10 | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101869687B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102579968A (en) * | 2011-01-14 | 2012-07-18 | 统欣生物科技股份有限公司 | Composition for improving liver function and reducing damage to liver |
| CN102178223B (en) * | 2011-04-08 | 2013-02-06 | 何鸿玲 | Ginkgo-onion capsule |
| CN102626164B (en) * | 2012-04-23 | 2013-06-12 | 北京绿源求证科技发展有限责任公司 | Liver nourishing tea granules for preventing alcoholic liver disease |
| JP6145552B1 (en) * | 2016-11-18 | 2017-06-14 | 正則 那須 | Fatty liver treatment composition |
| CN113559152B (en) * | 2021-09-27 | 2021-12-14 | 北京本草源生物科技有限公司 | Liver-protecting traditional Chinese medicine composition and beverage as well as preparation method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911421A (en) * | 2006-08-17 | 2007-02-14 | 吴金珠 | Fat-regulating and liver-tonifying type medicine for treating adiposis hepatica |
| CN1985978A (en) * | 2006-12-13 | 2007-06-27 | 上海莱博生物科技有限公司 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
| CN100998703A (en) * | 2006-12-28 | 2007-07-18 | 银小龙 | Medicine used for reducing weight, regulating fat metabolism and reducing blood fat |
| CN101019888A (en) * | 2006-12-28 | 2007-08-22 | 银小龙 | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase |
-
2010
- 2010-06-10 CN CN2010102011040A patent/CN101869687B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1911421A (en) * | 2006-08-17 | 2007-02-14 | 吴金珠 | Fat-regulating and liver-tonifying type medicine for treating adiposis hepatica |
| CN1985978A (en) * | 2006-12-13 | 2007-06-27 | 上海莱博生物科技有限公司 | Compound preparation for reducing fat deposit in liver and alleviating fatty degeneration of liver cell |
| CN100998703A (en) * | 2006-12-28 | 2007-07-18 | 银小龙 | Medicine used for reducing weight, regulating fat metabolism and reducing blood fat |
| CN101019888A (en) * | 2006-12-28 | 2007-08-22 | 银小龙 | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase |
Non-Patent Citations (2)
| Title |
|---|
| 陈玉等.酒精性肝病的中医治疗.《光明中医》.2007,第22卷(第11期),第32-33页. * |
| 高雅文等.脂肪肝的病因及中医辨证分型论治进展.《浙江中医学院学报》.2003,第27卷(第6期),第101-102页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101869687A (en) | 2010-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sweeney et al. | Evidence-based systematic review of dandelion (Taraxacum officinale) by natural standard research collaboration | |
| CN101869687B (en) | Medicament for treating fatty liver and alcohol liver, and reducing blood lipid and aminotransferase | |
| CN101596230B (en) | Medicinal composition for treating hepatopathy | |
| CN101019888A (en) | Medicine for treating fatty liver and alcoholic hepatitis and reducing blood fat and transaminase | |
| CN101607074A (en) | A kind of drug regimen for the treatment of chronic gastritis and preparation method thereof | |
| CN104703616A (en) | Formulations for the treatment and prevention of obesity | |
| CN103386043B (en) | Chinese medicine preparation for treating hyperuricemia | |
| CN102091141A (en) | Medicament for treating gout and preparation method thereof | |
| CN103705578B (en) | There is blood fat reducing and Chinese medicine preparation suppressing blood glucose rising effect and preparation method thereof | |
| CN102631425B (en) | Mongolian medicine for treating dyslipidemia | |
| CN102335255B (en) | Chinese medicine for treating hyperlipidemia and fatty liver and preparation method thereof | |
| CN101919985A (en) | Drug for treating fatty liver and preparation method and use thereof | |
| CN100579544C (en) | Chinese medicament preparation for treating cholecystitis and gall-stone as well as preparation method thereof | |
| CN101642541B (en) | Composition with hepatoprotective effect, preparation method and application thereof | |
| CN101468056B (en) | Chinese medicine preparation for treating enteritis, diarrhea, and red-white dysentery | |
| WO2010037255A1 (en) | The usage of ginseng and gynostemma pentaphyllum compound preparation in manufacture of medicaments with the effects of lipid regulation and blood-sugar regulation | |
| CN100418572C (en) | Oral Chinese medicine preparation for treating liver and gall bladder diseases | |
| WO2005072757A1 (en) | Imperatae rhizoma extract for treatment and prevention of obesity | |
| CN105169187B (en) | A kind of composition and its application, preparation method and drug, food containing the composition | |
| Ding et al. | Antifatigue effects of polydatin from Chinese herb Polygonum Cuspidatum in swimming mice | |
| CN101670046A (en) | Chinese medicinal composition for gastritis and esophagitis and preparation process thereof | |
| CN101961372A (en) | Traditional Chinese medicine for treating tumors by matching with Chinese brake herb and preparation method thereof | |
| CN100546598C (en) | A kind of oral liquid of eliminating hydrops and promoting graft function | |
| CN101167915B (en) | Traditional Chinese medicine for treating chronic superficial gastritis and its preparation method | |
| CN102335239B (en) | Chinese medicinal composition for reducing blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |